Hematology Division
Alphabetical list (active faculty):   
Amy W. Zhou

Amy W. Zhou, MD

Assistant Professor

Department of Medicine

Hematology Division

Research Interests

  • MPN
  • Myelofibrosis
  • Leukocytosis
  • Polycythemia
  • Thrombocytosis
  • Anemia
  • Cytopenias


  • 314-362-8814 (office)
  • Hematology Division
    Mail Stop 8125-0022-01
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Suite 1101 Wohl Hospital (office)

Peer-reviewed Manuscripts

  • Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Remains Elevated in Patients Treated With Ruxolitinib
    Zhou A, Kong T, Fowles JS, Jung CL, Allen MJ, Fisher DAC, Fulbright M, Nemeth E, Ganz T, Oh ST
    Br J Haematol 2022 May;197(4):e49-e52
  • Roxadustat for the Treatment of Anemia in Patients With Lower-Risk Myelodysplastic Syndrome: Open-Label, Dose-Selection, Lead-In Stage of a Phase 3 Study
    Henry DH, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway HE, Bradley C, Saha G, Modelska K, Bartels P, Leong R, Yu KP
    Am J Hematol 2022 Feb 1;97(2):174-184
  • Cytokine Production in Myelofibrosis Exhibits Differential Responsiveness to JAK-STAT, MAP Kinase, and NFkappaB Signaling
    Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST
    Leukemia 2019 Aug;33(8):1978-1995
  • Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience
    Trikalinos NA, Zhou A, Doyle MBM, Fowler KJ, Morton A, Vachharajani N, Amin M, Keller JW, Chapman WC, Brunt EM, Tan BR
    J Natl Compr Canc Netw 2018 Oct;16(10):1193-1199
  • An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?
    Zhou A, Holmes HM, Hurria A, Wildes TM
    Drugs Aging 2018 May;35(5):459-465
  • Mass Cytometry Analysis Reveals Hyperactive NF Kappa B Signaling in Myelofibrosis and Secondary Acute Myeloid Leukemia
    Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST
    Leukemia 2017 Sep;31(9):1962-1974
  • Cholesterol Esterification Inhibition and Imatinib Treatment Synergistically Inhibit Growth of BCR-ABL Mutation-Independent Resistant Chronic Myelogenous Leukemia
    Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX
    PLoS One 2017 Jul 18;12(7):e0179558
  • Clinical Improvement With JAK2 Inhibition in Chuvash Polycythemia
    Zhou AW*, Knoche EM*, Engle EK*, Ban-Hoefen M, Kaiwar C, Oh ST (*co-first author)
    N Engl J Med 2016 Aug 4;375(5):494-6
  • Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma
    Zhou A, Amin M, Fowler KJ, Brunt EM, Keller J, Tan B
    J Natl Compr Canc Netw 2015 Dec;13(12):1468-73
  • Outcomes of Platelet Transfusion in Patients With Thrombotic Thrombocytopenic Purpura: A Retrospective Case Series Study
    Zhou A, Mehta RS, Smith RE
    Ann Hematol 2015 Mar;94(3):467-72
  • Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated With Ruxolitinib and Dasatinib
    Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST
    Blood Cancer J 2015 Oct 2;5:e351
  • End-Of-Life Care Planning: Improving Documentation of Advance Directives in the Outpatient Clinic Using Electronic Medical Records
    Hayek S, Nieva R, Corrigan F, Zhou A, Mudaliar U, Mays D, Massoomi M, Ilksoy N
    J Palliat Med 2014 Dec;17(12):1348-52
  • Is the Incidence of Heparin-Induced Thrombocytopenia Affected by the Increased Use of Heparin for VTE Prophylaxis?
    Zhou A, Winkler A, Emamifar A, Gartland B, Duncan A, Antun A, Arellano M, Tindol GA, Levy JH, Bornstein WA, Horowitz IR, Khoury HJ
    Chest 2012 Nov;142(5):1175-78

Invited Publications

  • Chapter 21: Hematologic Disorders and Transfusion Therapy
    Patel B, Zhou A, Saif Ur Rehman S, Zhang R
    In: The Washington Manual of Medical Therapeutics, 37th ed. Philadelphia: Wolters Kluwer; In press
  • Chapter 39: Growth Factor Support in Oncology
    Weg M, Zhou A
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
    Fisher DAC, Fowles JS, Zhou A, Oh ST
    Front Immunol 2021 Jun 1;12:683401
  • Chapter 21: Hematologic Disorders and Transfusion Therapy
    Zhou A, Ferraro F, Jackups R, Blinder M
    In: The Washington Manual of Medical Therapeutics, 36th Edition (Crees Z, Fritz C, Heudebert A, Noe J, Rengarajan A, Wang X, editors), Wolters-Kluwer, Philadelphia, 2020
  • Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Pathophysiology and Molecular Mechanisms of Disease
    How J, Zhou A, Oh ST
    Ther Adv Hematol 2017 Mar;8(3):107-118
  • Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Review of the Recent Literature
    Zhou A, Afzal A, Oh ST
    Curr Hematol Malig Rep 2017 Oct;12(5):397-405
  • Chapter 21: Hematologic Disorders and Transfusion Therapy
    Zhou A, Regenbogen T, Jackups R, Blinder M
    In: Washington Manual of Medical Therapeutics, 35th ed. Philadelphia: Wolters Kluwer; 2016
  • Chapter 9: Myeloproliferative Disorders
    Zhou A
    In: Washington University Hematology Oncology Consult Manual, 4th ed. Philadelphia: Wolters Kluwer; 2016
  • Chapter 8: Myelodysplasia, Bone Marrow Failure Syndromes, and Other Causes of Pancytopenia
    Zhou A
    In: Washington University Hematology Oncology Consult Manual, 4th ed. Philadelphia: Wolters Kluwer; 2016
  • Prognostication in MF: From CBC to Cytogenetics to Molecular Markers
    Zhou A, Oh ST
    Best Pract Res Clin Haematol 2014 Jun;27(2):155-64